Alba López Ruiz, a predoctoral researcher in the Medicinal Chemistry and Pharmacology group at the University of Barcelona, participated—together with Prof. Carmen Escolano, Principal Investigator of the project—in the Investors Day of the Pla d’Acompanyament associated with the Producte 2024 grant, awarded by AGAUR within the Knowledge Industry Programme (Programa Indústria del Coneixement).

The one-year mentoring program focused on knowledge valorization and technology transfer, providing training in areas such as intellectual property, business development, transfer strategies, and communication with stakeholders from the innovation ecosystem.

As the closing event of the program, an Investors Day was held on January 21st at the PRBB Auditorium (Centre for Genomic Regulation, CRG). A selected group of projects was invited to present their results and impact potential to a specialized audience, including investors and innovation and technology transfer professionals. Among the selected projects was “Progression of an innovative antiglioblastoma drug” led by Prof. Carmen Escolano, which focuses on the development of a novel therapeutic agent with potential application in glioblastoma treatment.

In this project, Alba López Ruiz acted as the entrepreneurial scientist and was responsible for presenting the project during the Investors Day. This event provided a valuable opportunity to showcase the project and explore future steps towards its transfer and further development.

This experience highlights the group’s commitment to translational research and to the training of researchers capable of driving the progression of novel therapeutic developments from the laboratory to society.